Soligenix Advances Novel CTCL Therapy with Visible Light Treatment
January 29, 2026 — Soligenix develops HyBryte™, a visible light-activated therapy for early-stage cutaneous T-cell lymphoma (CTCL), showing significant efficacy in clinical trials while minimizing safety risks.